Blood pressure, fluid retention and the cardiovascular risk of drugs

Future Cardiology

Volumn 8, Issue 4, 2012, Pages 489-493

  Blankfield, Robert P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

blood pressure; cardiovascular risk; cardiovascular safety; fluid retention; heart attacks; strokes; US FDA

Indexed keywords

ALKYLATING AGENT; ANESTHETIC AGENT; ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DECONGESTIVE AGENT; DRUG; EPHEDRINE DERIVATIVE; ESTROGEN; GESTAGEN; IBUPROFEN; METHYLPHENIDATE; NAPROXEN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PHENYLPROPANOLAMINE; ROFECOXIB; ROSIGLITAZONE; SIBUTRAMINE; TESTOSTERONE; TORCETRAPIB; UNINDEXED DRUG; VALDECOXIB; VARENICLINE;

BLOOD PRESSURE; CARDIOVASCULAR RISK; DRUG SAFETY; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SIDE EFFECT; STROKE;

ANTIPSYCHOTIC AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; DRUG APPROVAL; EDEMA; HUMANS; THIAZOLIDINEDIONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864848056     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.39     Document Type: Review

References (38)

1. Grossman E, Messerli FH. Drug-induced hypertension: An unappreciated cause of secondary hypertension. Am. J. Med. 125, 14-22 (2012)
2. Novak KK. (Ed.)Drug Facts and Comparisons. Wolters Kluwer Health Inc., MO,USA (2011)
3. Bombardier C, Lanine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520-1528 (2000)
4. Nussmeier NA, Whelton AA, Brown MT et al. Complications of the COX 2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 1352, 1081-1091 (2005)
5. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296, 1633-1644 (2006)
6. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364, 2021-2029 (2004)
7. Antman EM, Bennett JS, Dougherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: An update for clinicians: A statement from the American Heart Association. Circulation 115, 1634-1642 (2007)
8. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007)
9. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis CMAJ 183, 1359-1366 (2011)
10. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia CNS Drugs 24, 729-739 (2010)
11. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst. Rev. 2, CD008191 (2011)
12. Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J. Clin. Psychiatry 69, 889-898 (2008)
13. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903-1913 (2002)
14. Weber MA. The ALLHAT report: A case of information and misinformation. J. Clin. Hypertens. 5, 9-13 (2003)
15. Cooper WO, Habel LA, Sox CM et al. ADHD drugs and serious cardiovascular events in children and young adults. N. Engl. J. Med. 365, 1896-1904 (2011)
16. Habel LA, Cooper WO, Sox CM et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306, 2673-2683 (2011)
17. Nissen SE, Wolski E. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular cause. N. Engl. J. Med. 356, 2457-2471 (2007)
18. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298, 1189-1195 (2007)
19. Pantalone KM, Kattan MW, Yu C et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in Type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: A retrospective analysis. Acta Diabetol. 46, 145-154 (2009)
20. Hsaio FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: A retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 32, 675-690 (2009)
21. Basaria S, Coviello AD, Travison TG et al. Adverse events associated with testosterone administration. N. Engl. J. Med. 363, 109-122 (2010)
22. Johannsson G, Gibney J, Wolthers T, Leung KC, Ho KK. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. J. Clin. Endrocrinol. Metab. 90, 3989-3994 (2005)
23. Jacobson SL, Eicher A, Paul MS, Giraud GD, Morton MJ, Thornburg KL. The sequential effects of estrogen administration and hypertension on cardiac function in ewes. Am. J. Obstet. Gynecol. 179, 610-619 (1998)
24. Kamali P, Müllerx T, Lang U, Clapp JF 3rd. Cardiovascular responses of perimenopausal women to hormonal replacement therapy. Am. J. Obstet. Gynecol. 182, 17-22 (2000)
25. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56, 129-140 (1997)
26. Light KC, Hinderliter AL, West SG et al. Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. J. Hypertens. 19, 269-278 (2001)
27. Lundh B, Gardner FH. The effect of testosterone in pharmacological doses on plasma volume and on some serum proteins in patients with sickle cell anemia and in sexually impotent men. Scand. J. Clin. Lab. Invest. 28, 72-78 (1971)
28. Pelzer T, Jazbutyte V, Hu K et al. The estrogen receptor-alpha agonist 16a-LE2 inhibits cardiac hypertrophy and improves hemodynamic function in estrogen-deficient spontaneously hypertensive rats. Cardiovasc. Res. 67, 604-612 (2005)
29. Quan A, Chakravarty S, Chen JK et al. Androgens augment proximal tubule transport. Am. J. Physiol. Renal. Physiol. 287, F452-F459 (2004)
30. Rossouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002)
31. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006)
32. Alibhai SM, Duong-Hua M, Sutradhar R et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol. 27, 3452-3458 (2009)
33. Schramm TK, Gislason GH, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur. Heart J. 32, 1900-1908 (2011)
34. Blankfield RP. Calculated effect of fluid retention upon velocity of blood flow and turbulence: implications for atherosclerosis. Clin. Hemorheol. Microcirc. 47, 79-86 (2011)
35. Funk CD, FitzGerald GA. COX 2 inhibitors and cardiovascular risk. J. Cardiovasc. Pharmacol. 50, 470-479 (2007)
36. Yu Y, Ricciotti E, Grosser T, Fitzgerald GA. The translational therapeutics of prostaglandin inhibition in atherothrombosis. J. Thromb. Haemost. 7(Suppl. 1), 222-226 (2009)
37. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 298, 1180-1188 (2007)
38. Nagajothi N, Adigopula S, Balamuthusamy S et al. Pioglitazone and the risk of myocardial infarction and other adverse cardiac events: A meta-analysis of randomized, controlled trials. Am. J. Ther. 15, 506-511 (2008).